radiation pneumonitis
Conditions
Interventions
experimental group:Patients received CyberKnife therapy combined with oral administration of Bifidobacterium Tetragenous Viable Tablets (1 tablet per dose, 3 times daily), initiated 1 week before Cybe
control group:Patients received CyberKnife therapy
Sponsors
The First Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
35 Years to 80 Years
Inclusion criteria
Inclusion criteria: 35 to 80 years of age; pathologically confirmed diagnosis of primary lung cancer or secondary metastatic malignancy of the lung, with a planned CyberKnife treatment; Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1; granted consent to receive CBLEBTL adjunctive treatment and comply with follow-up requirements; an expected survival of at least 6 months; both patient and their family provided informed consent.
Exclusion criteria
Exclusion criteria: concurrently receiving chemotherapy, immunotherapy, or targeted therapy; those with chest computed tomography (CT) findings indicative of any pulmonary infection or interstitial lung fibrosis; those with comorbidities such as thromboembolism, heart failure, or uncontrolled hypertension; those simultaneously enrolled in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CT results of the chest; | — |
Secondary
| Measure | Time frame |
|---|---|
| ECOG score;symptoms;signs; | — |
Countries
China
Contacts
Public ContactQian Wang
The First Hospital of Hebei Medical University
Outcome results
None listed